MedTrace Logo

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

NCT00382200 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2024-05-20

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of myelodysplastic cells, either by killing the cells or by stopping them from dividing. Tretinoin and decitabine may help myelodysplastic cells become more like normal cells, and to grow and spread more slowly. Giving decitabine together with tretinoin may be an effective treatment for myelodysplastic syndromes.

PURPOSE: This phase I/II trial is studying the side effects and best dose of tretinoin when given together with decitabine in treating patients with myelodysplastic syndromes.

Conditions

Interventions

DRUG

decitabine

DRUG

tretinoin

GENETIC

DNA methylation analysis

GENETIC

cytogenetic analysis

GENETIC

microarray analysis

OTHER

flow cytometry

OTHER

immunohistochemistry staining method

Sponsors & Collaborators

Principal Investigators

  • Raajit Rampal, MD, PhD · Memorial SloanKettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2023-01-05
Completion
2023-01-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382200 on ClinicalTrials.gov